Fundraising Fox
CuePath Innovation
Techstars '17Vancouver, CA · Founded 2015 · British Columbia, Canada corporation · 4 employees on LinkedIn · 1 known investors
Find your way into CuePath Innovation
Sign up to see every warm intro you have to CuePath Innovation
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CuePath Innovation team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CuePath develops smart stickers that attach to medication blister packs to monitor and record real-time adherence data for clinical drug trials. The technology targets clinical research organizations and serves substance use disorder and addiction management studies across North America.
Also known as CuePath · CuePath Innovation Inc.
Founders & leadership
Investors · 1
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$59K disclosed across 1 round · 2022
▶$59KraisedNov 2022 · 2 investors · Other Health CareRule 506(b)
- Kirk MoirDirector
- Geof AuchinleckDirector
- Ken D. PiaggioExecutive Officer
- Jennifer ThompsonDirector
- Offering amount
- $80.9K
- Amount sold
- $59K
- Minimum investment
- $11.8K
- First sale
- Mar 2022
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Sep 2026CuePath Innovation is a Vancouver, British Columbia-based developer of medication adherence monitoring technology. Its flagship product, the CuePack, is a printed-electronic smart sticker (marketed as CueStickers) that attaches to standard pharmacy blister packs and automatically records the date and time each blister cavity is opened. Data is transmitted to CuePath's cloud gateway and synchronized with clinical trial management software, and the company states that no identifying patient information passes through its servers.
The technology is positioned for clinical researchers running large, distributed, placebo-controlled drug trials, particularly those involving controlled substances or high-value pill-based drugs, and was designed initially for addiction and pain management studies. It replaces participant self-reporting, reduces the need for daily witnessed ingestion and in-clinic visits, supports adverse event monitoring, and is intended to help detect and prevent diversion of controlled substances. CuePath provides customizable data exports and integration with platforms such as REDCap and other third-party systems.
At its 2015 founding the company pursued a different application of the same core idea: an internet-connected pill box and mobile app intended to help seniors and their caregivers manage complex medication regimens, integrated into pharmacy workflow using blister packaging patients were already familiar with.
Business model
CuePath sells its connected medication-packaging technology to clinical research buyers — contract research organizations, trial sponsors and academic research centres — deploying CuePack/CueSticker hardware alongside a cloud data service that feeds adherence data into the customer's clinical trial management system. Earlier, the company positioned the same blister-pack monitoring concept as a consumer/caregiver medication reminder and monitoring service distributed through pharmacies, and described bootstrapping through initial pilots before raising angel capital from a strategic partner.
▸Full profile — history
History
The company was launched in Vancouver, B.C. in 2015 by Victor Lesau and Ivan Spogreev and spent its early period validating the product through interviews with prospective customers and building prototypes. In 2017 it took part in the Techstars Seattle accelerator class, with an early team including engineers Yagnik Vadher and Walt Sacuta and product marketing manager Jeff Nider, and planned U.S. pilot rollouts in the Seattle region. The product focus later shifted from senior medication management toward clinical trial adherence monitoring, with the CuePack smart sticker deployed in the Canadian ASCME methamphetamine use disorder treatment trial and a stated 2025 objective of expanding partnerships across North American mental health and substance use research communities. Jennifer Thompson is listed as interim CEO, with Sharon Shi as VP Finance and Daisy Lee as VP, Global Manufacturing.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsCuePath supplies its smart-sticker adherence technology to the pan-Canadian, multisite ASCME clinical trial for methamphetamine use disorder treatment, funded by Health Canada and led by the University of Montreal Hospital Research Centre (CRCHUM), in partnership with BC-based CRO ChangeMark Research + Evaluation.
Co-founder and CEO Victor Lesau said the company bootstrapped through its first pilots and then raised an angel round with a strategic partner, with plans for later VC-backed financing. No amount was disclosed.
CuePath developed the company through the Techstars Seattle 2017 accelerator, preparing for Demo Day on April 19, 2017, and planned to roll out pilot products in Seattle and the surrounding region that year.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 4
primary sources listed
- CuePath Innovationcuepath.io · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does CuePath Innovation do?
- CuePath develops smart stickers that attach to medication blister packs to monitor and record real-time adherence data for clinical drug trials. The technology targets clinical research organizations and serves substance use disorder and addiction management studies across North America.
- Who are CuePath Innovation's investors?
- CuePath Innovation's investors include Techstars.
- How much funding has CuePath Innovation raised?
- CuePath Innovation has disclosed $59K raised across 1 round.
- Where is CuePath Innovation headquartered?
- CuePath Innovation is headquartered in Vancouver, CA.